Decision ruleHaematology

Bone marrow involvement risk in Hodgkin lymphoma (Vassilakopoulos)

Clinical rule estimating the probability of bone marrow involvement to decide whether a marrow biopsy is needed.

Updated 30 October 2026

When to use it

Initial staging of Hodgkin lymphoma when PET-CT is unavailable or marrow involvement is uncertain.

What it needs

  • B symptoms (fever, night sweats, weight loss > 10 %)Yes or no
  • Clinical stage III–IV before marrow biopsyYes or no
  • AnaemiaYes or no
  • White cells < 6 × 10⁹/LYes or no
  • Age ≥ 35 yearsYes or no
  • Iliac or inguinal nodal involvementYes or no

The points for each answer and the automatic total are in the app.

How to interpret it

Zs score
ResultInterpretation
≤ -1Low risk (≈ 0.3 %): biopsy may be omitted
0–9Standard risk (≈ 4 %): unilateral biopsy
≥ 10High risk (≈ 25 %): consider bilateral biopsy

Practical tip

With staging PET-CT, marrow biopsy is no longer routine: PET detects focal involvement more sensitively.

2 more practical tips in the app.

Reference

A support tool for healthcare professionals: it guides and does not replace clinical judgement.

Back to top